Despite some promising results, APR-246 is still the only mutant p53-reactivating molecule that reached an advanced stage of clinical investigation with a phase III clinical trial in TP53 mutant myelodysplastic syndrome (NCT03745716) [54]. Here, TP53 is linked to myelodysplastic syndrome.